NASDAQ Healthcare Medical - Devices LIVN

LivaNova PLC

$ 78.50 0.00 %

LivaNova PLC is a global medical technology company dedicated to developing, manufacturing, and marketing a variety of therapeutic solutions. The company operates through three key segments. Its Cardiopulmonary division provides essential products for heart-lung procedures, such as oxygenators, heart-lung machines, and various perfusion systems. The Neuromodulation segment is known for its VNS Therapy System, an implantable device that delivers vagus nerve stimulation to treat drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea. This segment is also advancing the VITARIA System, which employs VNS for heart failure, through clinical development. The Advanced Circulatory Support segment offers temporary life support solutions, including both cardiopulmonary and respiratory support technologies. LivaNova serves a wide range of medical professionals, including perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals and healthcare providers. The company's products are distributed globally through both its direct sales force and independent distributors. Additionally, LivaNova has a research collaboration with Verily aimed at discovering clinical biomarkers for depression. Founded in 1987, the company is headquartered in London, United Kingdom.

CEO: Vladimir A. Makatsaria - https://www.livanova.com

Summary 30-Y Financials Dividend Analyst Key metrics Ownership / Senat
Price objectif

$79.67 1.49 %

Recommandation

Buy

DCF

$ -13.27

Loading data...

LIVN vs S&P500

Loading data...

No data available.

Quick ratio

1.11

suggests a healthy liquidity position, showing that the company can likely meet its short-term obligations.

P/E ratio

40.05

is considered reasonable, suggesting that the company has a valuation in line with its current profits.

EPS

1.96

is the net profit of a company divided by the number of outstanding shares, indicating the profit earned per share.

ROE

9.13 %

indicates low profitability, suggesting that the company is not using equity efficiently to generate profits.

ROIC

10.19 %

generates a return higher than the cost of its capital, thereby creating value for its investors.

WACC

8.34

is a company's average cost of capital, weighted by the proportion of debt and equity in its financing. It represents the minimum return the company must generate to satisfy its investors.

Debt-to-Equity Ratio

0.28

indicates that the company uses more equity than debt, suggesting prudent management.

Free cash flow per share

2.94

is a measure of a company's financial flexibility that is determined by dividing free cash flow by the total number of shares outstanding.

Dividend payout ratio

0.00 %

the dividend payout ratio is the measure of dividends paid out to shareholders relative to the company's net income.

Earnings per share

Loading data...

No data available.

Financials

Piotroski score
6 indicates moderate financial health
Altman score
2.27 indicates an uncertain financial situation
Loading data...

No data available.

Cash / Debt

Cash Ratio
0.71 indicates that the company has a moderate ability to cover its short-term debts with its cash
Debt Ratio
0.13 indicates that the company uses little debt to finance its assets, suggesting good financial stability
Loading data...

No data available.

Free Cash Flow

Loading data...

No data available.

Earnings Per Share (annual)

Loading data...

No data available.

Sales

Loading data...

No data available.